RNA, U6 small nuclear 808, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-808P profile across patient tissues and cancer cell-line models. RNU6-808P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNU6-808P is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, RNU6-808P RNA expression shows 7,547 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, KICH, and THYM as cancer lineages where RNU6-808P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-808P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-808P survival associations across molecular data types. RNU6-808P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-808P RNA expression–survival associations across cancer types. High RNU6-808P expression shows unfavorable associations in CESC, UCEC, KIRC, KIRP, CHOL and COAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for RNU6-808P RNA expression.
This table summarizes RNU6-808P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-808P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-808P shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, CHOL and STAD. The KICH box plot shows higher RNU6-808P RNA expression in normal versus tumor tissue (log2 FC = −0.297, t-test p = .002).
This table shows molecular features associated with RNU6-808P in patient tissues and cancer cell lines. In patient samples, RNU6-808P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
